KMT2A and leukemia: To simulate the clinical setting, we transplanted Tgif1+/+ and Tgif1−/−, MLL‐AF9‐transformed‐spleen cells from mice with established leukaemia into sub‐lethally irradiated recipients and treated these mice with cytarabine and doxorubicin chemotherapy as described.19